Clinical Trial Update: Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pre-treatment with azithromycin to reduce immunogenicity to anti-TNF therapy in Crohn's disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Azithromycin (azithromycin)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Crohn's Disease Relapse, Biological Substance; Adverse Effect | Phase 2 | Status: RECRUITING